This study is not yet accepting patients

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

a study on Lymphoma Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma Hematologic Malignancy

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco 5391959, California 5332921 and other locations
Dates
study started
study ends around

Description

Summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Official Title

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

Keywords

Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Rituximab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:
    • Diffuse large B-cell lymphoma - not otherwise specified
    • High-grade B-cell lymphoma
    • Follicular large B-cell lymphoma
    • Follicular lymphoma
    • Other non-Hodgkin lymphoma
  • Has measurable disease
  • Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

You CAN'T join if...

  • Has an active second cancer
  • Has known or suspected history of central nervous system involvement
  • Has known Cytomegalovirus infection. Participants with negative status are eligible
  • Has known hepatitis B or C infection or HIV
  • Has significant heart disease

Locations

  • UCSF (UCSF) - Helen Diller Family Comprehensive Cancer Center
    San Francisco 5391959 California 5332921 94158 United States
  • City of Hope
    Duarte 5344147 California 5332921 91010 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT07226843
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 360 study participants
Last Updated